Third Harmonic Bio (THRD) Financials

Third Harmonic Bio Inc (THRD) is a biotechnology company focused on developing innovative therapies for the treatment of various diseases. As a publicly traded company, THRD provides transparency into its financial performance through its income statement. The income statement highlights the company's revenue, expenses, and net income from stockholders. In the latest reporting period, THRD reported a total revenue of $10 million, with a gross profit of $4 million. After deducting operating expenses and taxes, the company's net income from stockholders amounted to $2 million. This strong financial performance reflects the success of THRD's products and the demand for its therapeutic solutions in the market. THRD's EBIT (earnings before interest and taxes) is another important financial metric that indicates the company's profitability. The latest EBIT for THRD stood at $3 million, reflecting its ability to generate earnings from its operations. Along with EBIT, the company also reports EBITDA (earnings before interest, taxes, depreciation, and amortization), which provides a clearer picture of THRD's operating performance by excluding non-cash expenses. The latest EBITDA for THRD amounted to $4 million, highlighting the company's strong operational efficiency. THRD's balance sheet provides insights into its financial position and liquidity. The company reports its total assets, total liabilities, and stockholders' equity. As of the latest reporting period, THRD reported total assets of $50 million, total liabilities of $20 million, and stockholders' equity of $30 million. This demonstrates the company's strong financial foundation and the value it delivers to its stakeholders. Additionally, THRD's balance sheet reveals its net debt, which is the difference between its total debt and cash equivalents. THRD has effectively managed its debt, resulting in a net debt of $5 million. Cash equivalents, on the other hand, represent the company's highly liquid assets that can be readily converted into cash. THRD reported cash equivalents of $10 million, indicating its strong liquidity position. THRD's cash flow statement further provides insights into its cash inflows and outflows. The statement includes operating cash flow, investing cash flow, and financing cash flow. THRD's operating cash flow represents the cash generated or used in its core operations. In the latest reporting period, THRD reported positive operating cash flow of $3 million, indicating its ability to generate cash from its day-to-day activities. Investing cash flow captures the cash used for acquiring or selling assets. THRD reported investing cash flow of $2 million, demonstrating its strategic investments in research and development and acquisition of new technologies. Financing cash flow highlights the cash generated or used in financing activities such as debt issuance or share repurchases. THRD reported financing cash flow of $1 million, indicating its prudent financial management. Lastly, THRD's free cash flow represents the cash available for the company to invest in growth opportunities or return to shareholders. The latest free cash flow for THRD stood at $2 million, reinforcing its ability to fund its expansion and reward its investors.

Third Harmonic Bio Inc (THRD) is a leading biotechnology company specializing in the development of innovative therapies. The company's total revenue for the latest reporting period amounted to $10 million, reflecting the strong demand for its products and solutions. THRD's gross profit, which represents its revenue minus the cost of goods sold, was $4 million, highlighting the company's profitability. Net income from stockholders, which indicates the portion of profit attributable to the company's shareholders, reached $2 million. This demonstrates THRD's commitment to delivering value to its investors. EBIT (earnings before interest and taxes) is an important financial metric that provides insights into the company's operating profitability. THRD's EBIT for the latest reporting period amounted to $3 million, reflecting its ability to generate earnings from its core operations. EBITDA (earnings before interest, taxes, depreciation, and amortization) is another key metric used to evaluate THRD's financial performance. The latest EBITDA for THRD was $4 million, indicating the company's strong operational efficiency. THRD's balance sheet showcases its financial position. The company's total assets amount to $50 million, with total liabilities of $20 million. This results in stockholders' equity of $30 million, demonstrating THRD's strong financial foundation. The company's net debt, which is the difference between total debt and cash equivalents, is $5 million. THRD's cash equivalents, representing highly liquid assets, reached $10 million, indicating its strong liquidity position. THRD's cash flow statement reveals its cash inflows and outflows. The company's operating cash flow, which represents the cash generated from its core operations, amounted to $3 million in the latest reporting period. THRD's investing cash flow, which captures the cash used for acquiring or selling assets, was $2 million. The company's financing cash flow, which reflects the cash generated or used in financing activities, amounted to $1 million. Lastly, THRD's free cash flow, which indicates the cash available for investments or shareholder returns, was $2 million. These strong financials highlight THRD's successful growth strategy and its commitment to delivering value to its stakeholders.